Clinical Trial TitleACTIV-2: A Study for Outpatients With COVID-19
National Clinical Trial Number:NCT04518410
Clinical Trial Protocol Description:
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will be treated with either a study drug or with placebo and will have 28 days of intensive follow-up following study drug administration, followed by limited follow-up through 24 weeks. Study visits may be required after week 24 depending on the study agent.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Have CURRENT Covid-19 infection.
- Have a documented positive Covid-19 test for current infection.
You will be excluded from the study if any of the following criteria apply to you:
- Have received convalescent Covid-19 plasma or antibody-based Covid-19 treatment or prophylaxis at any time.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.